Bio Preventive Medicine to Showcase Groundbreaking Clinical Milestones at EASD 2026 in Milan
Bio Preventive Medicine to Showcase Groundbreaking Clinical Milestones at EASD 2026 in Milan
Selected for Prestigious Oral Presentation and Welcoming Global Partners at Booth F.08
EASD 2026 Oral Presentation
Session OP40: What the kidney is telling us: new biomarkers in diabetic nephropathy
-
Title:
Urinary Post-Translationally Modified Fetuin-A Predicts Renal Outcomes Independent of Albuminuria and eGFR in Type 2 Diabetes and Chronic Kidney Disease -
Date & Time:
Friday, October 2, 2026 | 10:00 AM – 11:00 AM (CEST) -
Room / Venue:
Budapest Hall, Allianz MiCo, Milan Convention Centre
BPM Exhibition Booth
Connecting with global endocrinologists, nephrologists, and distribution partners
-
Exhibition Dates:
September 29 – October 1, 2026 -
Location:
Allianz MiCo Exhibition Hall, Milan, Italy -
Exhibition Highlights:
Showcasing DNlite™ (DNlite-IVD103) for non-invasive DKD prognosis, clinical guideline inclusions, international multicenter validations, and commercial distribution licensing.
Scientific Breakthrough: Overcoming Clinical Blind Spots in Diabetic Kidney Disease
The oral presentation selected by the EASD scientific committee addresses fundamental challenges in contemporary nephrology and diabetic care:
Predicting Adverse Renal Outcomes Independent of Albuminuria (UACR) & eGFR
Standard screening tools such as estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) suffer from structural latency and cannot adequately capture non-albuminuric diabetic kidney disease (NA-DKD) or active parenchymal stress. DNlite™ quantifies urinary post-translationally modified Fetuin-A (uPTM-FetA), providing an early molecular window into cellular injury and inflammation prior to irreversible renal fibrosis.
Unmasking "Residual Renal Risk" in the Era of SGLT2 Inhibitors
Despite the widespread adoption of SGLT2 inhibitors as guideline-directed medical therapy, a significant proportion of patients with type 2 diabetes continue to suffer from progressive kidney decline. BPM’s findings demonstrate that uPTM-FetA accurately identifies patients who remain at high residual renal risk, providing clinicians with vital guidance for timely therapy optimization and combination regimens.
Enabling Timely Clinical Decisions & Personalized Therapy
As a non-invasive in vitro diagnostic (IVD) test, DNlite™ empowers clinicians to implement risk stratification for rapid decline, seize the golden therapeutic window, improve patient outcomes, and reduce the socioeconomic burden of end-stage renal disease (ESRD) and dialysis.
Meet Us in Milan! Schedule a One-on-One Partnering Meeting
Whether you are a practicing clinician, clinical investigator, IVD distributor, or strategic pharmaceutical partner, we invite you to connect with BPM leadership at Booth F.08 or attend our Oral Presentation (Budapest Hall) to explore regional commercialization and research collaborations.
Book a Meeting with BPM (dnlite@bpmbiotech.com)About Bio Preventive Medicine Corp. (BPM)
Bio Preventive Medicine Corp. (BPM; TPEx: 6810), established in 2014, is a clinical-stage biotechnology pioneer dedicated to the discovery of novel translational biomarkers and the commercial development of innovative in vitro diagnostic (IVD) solutions. Specializing in post-translationally modified protein biomarkers, BPM’s proprietary DNlite™ (DNlite-IVD103) is the world’s first non-invasive urinary assay designed for predicting diabetic kidney disease (DKD) progression and monitoring renal graft outcomes. DNlite™ has obtained regulatory approvals across key international markets and is officially incorporated into clinical practice guidelines.
Contact: Tel: +886 3 560 1816 | Website: www.bpmbiotech.com | Email: dnlite@bpmbiotech.com
Related News
BPM Debuts DNlite-IVD103 at the 57th ERA-EDTA Congress
Securing Early Wins in European and US Markets
2020/06/05
Events
BPM Showcases DNlite-IVD103 at MEDICA 2023, Accelerating European Expansion Following Major Clinical Validations
BPM Showcases DNlite-IVD103 at MEDICA 2023, Accelerating European Expansion Following Major Clinical Validations
2023/11/14
Events
BPM Debuts World’s First Type 1 Diabetes Clinical Data for DNlite-IVD103 at MKS 2022, Accelerating European Expansion
BPM Debuts World’s First Type 1 Diabetes Clinical Data for DNlite-IVD103 at MKS 2022, Accelerating European Expansion
2022/09/30
Events